Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer (THY-CANC)

August 1, 2025 updated by: Istituto Auxologico Italiano

Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer

DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.

Study Overview

Status

Recruiting

Conditions

Thyroid Cancer

Study Type

Observational

Enrollment (Estimated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Laura Fugazzola, MD
Phone Number: 2727 +390261911
Email: l.fugazzola@auxologico.it

Study Locations

Italy
- - Milan, Italy, 20149
    - Recruiting
    - Istituto Auxologico Italiano, IRCCS
    - Contact:
      
      Laura Fugazzola, MD
      
      Phone Number: +3902619112727
      
      Email: l.fugazzola@auxologico.it

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

all consecutive patients referred to our tertiary clinical center for thyroid cancer

Description

Inclusion Criteria:

- thyroid cancer diagnosis

Exclusion Criteria:

patients unable to sign informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dynamic risk stratification Time Frame: one year from the primary treatment	impact of the different variables on the DRS	one year from the primary treatment
Dynamic risk stratification Time Frame: five years from the primary treatment	impact of the different variables on the DRS	five years from the primary treatment
Dynamic risk stratification Time Frame: ten years from the primary treatment	impact of the different variables on the DRS	ten years from the primary treatment
Progression-free survival Time Frame: one year from the primary treatment	impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer	one year from the primary treatment
Progression-free survival Time Frame: five years from the primary treatment	impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer	five years from the primary treatment
Progression-free survival Time Frame: ten years from the primary treatment	impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer	ten years from the primary treatment
Overall survival Time Frame: one year from the primary treatment	impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer	one year from the primary treatment
Overall survival Time Frame: five years from the primary treatment	impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer	five years from the primary treatment
Overall survival Time Frame: ten years from the primary treatment	impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer	ten years from the primary treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Auxologico Italiano

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 12, 2022

Primary Completion (Estimated)

March 8, 2032

Study Completion (Estimated)

March 8, 2042

Study Registration Dates

First Submitted

February 17, 2023

First Submitted That Met QC Criteria

March 1, 2023

First Posted (Actual)

March 2, 2023

Study Record Updates

Last Update Posted (Actual)

August 3, 2025

Last Update Submitted That Met QC Criteria

August 1, 2025

Last Verified